In Reply
- PMID: 33826783
- PMCID: PMC8265353
- DOI: 10.1002/onco.13782
In Reply
Abstract
This letter to the editor responds to Badoui et al. regarding data on abemaciclib dosages and adverse events.
Comment on
-
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.Oncologist. 2021 Jan;26(1):e53-e65. doi: 10.1002/onco.13531. Epub 2020 Oct 9. Oncologist. 2021. PMID: 32955138 Free PMC article.
-
Regarding the Article by Rugo et al.Oncologist. 2021 Jul;26(7):e1285. doi: 10.1002/onco.13781. Epub 2021 Apr 28. Oncologist. 2021. PMID: 33818868 Free PMC article.
References
-
- Rugo H, Huober J, García‐Sáenz J et al. Management of abemaciclib‐associated adverse events in patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. The Oncologist 2021;26:e53–e65. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
